b'FIGHTING CANCER WITH AUNIQUE CLINICAL AND SINGLECELL MULTIOMICS DATABASEONCOVERITY, INC.OncoVerity, Inc. CEO Max Colao understandsSingle-cell analysis can provide deep the journey patients and their caregiversinsights to how cancer thrives and escapes embarkonwhentheyrebattlingcancer.treatment, Colao said. Were leveraging After all, Colaos 23-year-old son Jacob hasthis scientific approach so that we can been battling a rare type of sarcoma calleddevelop precision medicines that trans-Gastrointestinal Neuroectodermal Tumor forform hope to reality for patients, caregivers, the past seven years.and families.Colao, who joined OncoVerity in January, wantsOncoVerity has secured the worldwide to ensure patients with acute myeloid leukemialicensing rights for experimental cancer (AML) who are underserved get the standardtherapy cantuzumab. It is studying hema-of care they deserve. The company has identi- tologic malignancies, including a Phase 1b fied groups of high-risk AML patients whose lifetrial for patients with AML.expectancy is six to nine months. Hes workingCU Anschutz, UCHealth, and argenx created closely with Chief Medical Officer Clay Smith,the asset-centric spinoff OncoVerity, the M.D., who has more than 30 years of experi- first deal to come out of CU Innovations. ence in oncology research, clinical care, andIt received $30 million in funding from clinical trials.argenx and a joint venture of UCHealth and The company uses a clinical and single cell mul- University License Equity Holdings for the tiomics database to improve the lives of patientscontinued development of cusatuzumab, an battlingcancer.Thecompanysapproachanti-CD70 antibody with promising results leverages the University of Colorado Anschutzin early AML studies. Medical Campus and UCHealth infrastructure of single-cell analysis capabilities.Max Colao, M.B.A., CEO, OncoVerity, Inc.Were leveraging this scientific approachso that we can develop precision medicines that transform hope to reality for patients, caregivers, and families.MAX COLAO, M.B.A.CEOOncoVerity, Inc.18 BIOSCIENCE COLORADO 2023-2024'